Mannkind reported $-12790000 in Operating Profit for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Adma Biologics ADMA:US USD 29.75M 39.06M
Biocryst Pharmaceuticals BCRX:US USD -46311000 28.87M
Dynavax Technologies DVAX:US USD 63.14M 1.74M
Eli Lilly And LLY:US USD 1.84B 159.9M
Halozyme Therapeutics HALO:US USD 74.51M 6.07M
Immunogen IMGN:US USD -59559000 17.87M
Insmed INSM:US USD -151475000 23.78M
JAZZ PHA JAZZ:US USD -263386000 288.15M
Karyopharm Therapeutics KPTI:US USD -33869000 3.03M
Macrogenics MGNX:US USD 11.98M 36.94M
Mannkind MNKD:US USD -12790000 3.18M
Merk MRK:US USD 3.51B 505M
Minerva Neurosciences NERV:US USD -5070000 137K
Novavax NVAX:US USD -243879000 116.69M
Novo Nordisk A Fs NVO:US DKK 17.09B 3.1B
Pfizer PFE:US USD 5.17B 4.24B
Xencor XNCR:US USD -42693000 4.34M